MetaCap

Relay Therapeutics Inc. (RLAY)

NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

16.12+0.21 (+1.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RLAY stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.50
52-week range
6.80 – 21.27
Day range
15.17 – 16.32
Volume / Avg
3.98M / 2.93M
Beta
—

52-week range

$6.80$21.27

RLAY stock today

Relay Therapeutics (RLAY) closed at $16.12 on Nov 20, up 1.32% (+$0.21), versus the S&P 500's 3.70% decline. At this level, RLAY sits in the middle of its 52-week range of $6.80 to $21.27: 24.2% below the high, set on Aug 19, 2026 and 137.1% above the low. RLAY is up 90.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 138.1%.

Relay Therapeutics has posted a net loss over the last twelve months (EPS of -$1.50), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Relay Therapeutics

Company profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Headquarters
Cambridge, MA
Employees
218
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Relay Therapeutics generated $15.4 million in revenue, up 53.4% from fiscal 2024. Relay Therapeutics reported a net loss of $276.5 million, compared with a loss of $337.7 million a year earlier. Operating margin was -1971.6%.

Relay Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$15.36M$10.01M$25.55M$1.38M$3.03M
Growth+53.44%-60.83%+1749.82%-54.41%-96.34%
Net income$-276.48M$-337.71M$-341.97M$-290.51M$-363.87M
EPS (diluted)$-1.61$-2.36$-2.79$-2.59$-3.82

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$28.25+75.25%

  • Strong buy 3
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $25.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.37 vs $-0.40
Surprise
+7.50%

RLAY news

All RLAY news

Relay Therapeutics peers

Health Care sector
RLAY peer companies
CompanyPrice% ChgMarket capCompare
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs RLAY
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs RLAY
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs RLAY
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs RLAY
VCELVericel Corporation57.52-1.27%$2.94Bvs RLAY
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs RLAY
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs RLAY
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs RLAY

Indexes, lists and sector

Relay Therapeutics stock FAQ

What is Relay Therapeutics's stock price today?

RLAY last traded at $16.12 as of Nov 20, 4:00 PM EST, up 1.32% on the day. Prices are delayed at least 15 minutes.

Who is Relay Therapeutics's CEO?

Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS is the chief executive officer of Relay Therapeutics Inc., which has about 218 employees.

What is the RLAY 52-week high?

The 52-week high for RLAY is $21.27 and the 52-week low is $6.80. The stock is currently 24.2% below its high.

Compare RLAY